Experiences and Treatment Preferences in Patients With Psoriatic Arthritis: A Cross-Sectional Study in the ArthritisPower Registry.
Best–worst scaling
Disease impacts
Joint pain
Patient preferences
Psoriatic arthritis
Journal
Rheumatology and therapy
ISSN: 2198-6576
Titre abrégé: Rheumatol Ther
Pays: England
ID NLM: 101674543
Informations de publication
Date de publication:
Apr 2022
Apr 2022
Historique:
received:
17
12
2021
accepted:
25
02
2022
pubmed:
14
3
2022
medline:
14
3
2022
entrez:
13
3
2022
Statut:
ppublish
Résumé
Despite recent advances in treatment for psoriatic arthritis (PsA), many patients experience inadequate response or intolerance to therapy, indicating that unmet treatment-related needs remain. To further characterize these unmet needs, we evaluated patients' experiences regarding the burden of PsA symptoms and disease impacts, and patients' preferences for treatment. Patients from ArthritisPower, a rheumatology research registry, completed a web-based survey. Object case best-worst scaling (BWS) was used to evaluate the relative burden of 11 PsA-related symptoms and the relative importance of improvement in nine PsA-related disease impacts. BWS data were analyzed using a random-parameters logit model. Patient demographics, preferences for mode and frequency of therapy, and preferences for methotrexate were analyzed descriptively. Among the 332 participants, most were White (94%), female (80%), with mean age of 54 years (SD 11.4). In the BWS, joint pain was the most bothersome symptom, followed by other musculoskeletal pain and fatigue. The BWS for disease impacts found that improvements in the ability to perform physical activities were most important, followed by improvements in the ability to function independently, sleep quality, and the ability to perform daily activities. The most burdensome symptoms and desired disease impact improvements were similar in patients regardless of their experience with biologic disease-modifying antirheumatic drugs. The most preferred mode and frequency of treatment administration was oral, once-daily medication (preferred by 38% of respondents), and 74% prioritized therapies that significantly improved joint-related symptoms versus psoriasis-related symptoms. The majority of respondents (65%) preferred PsA treatment regimens that did not include methotrexate. Patients with PsA from a rheumatology registry found musculoskeletal pain symptoms to be the most bothersome and prioritized improvements to functional impacts of their disease. These findings can better inform development of new therapies and guide shared patient-provider treatment decision-making.
Identifiants
pubmed: 35279798
doi: 10.1007/s40744-022-00436-x
pii: 10.1007/s40744-022-00436-x
pmc: PMC8964868
doi:
Types de publication
Journal Article
Langues
eng
Pagination
735-751Commentaires et corrections
Type : ErratumIn
Informations de copyright
© 2022. The Author(s).
Références
Alinaghi F, Calov M, Kristensen LE, Gladman DD, Coates LC, Jullien D, et al. Prevalence of psoriatic arthritis in patients with psoriasis: a systematic review and meta-analysis of observational and clinical studies. J Am Acad Dermatol. 2019;80(1):251-65 e19. https://doi.org/10.1016/j.jaad.2018.06.027 .
doi: 10.1016/j.jaad.2018.06.027
pubmed: 29928910
Chandran V, Raychaudhuri SP. Geoepidemiology and environmental factors of psoriasis and psoriatic arthritis. J Autoimmun. 2010;34(3):J314–21. https://doi.org/10.1016/j.jaut.2009.12.001 .
doi: 10.1016/j.jaut.2009.12.001
pubmed: 20034760
Lebwohl MG, Bachelez H, Barker J, Girolomoni G, Kavanaugh A, Langley RG, et al. Patient perspectives in the management of psoriasis: results from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis Survey. J Am Acad Dermatol. 2014;70(5):871-881 e1-30. https://doi.org/10.1016/j.jaad.2013.12.018 .
doi: 10.1016/j.jaad.2013.12.018
pubmed: 24576585
Ogdie A, Coates L. The changing face of clinical trials in psoriatic arthritis. Curr Rheumatol Rep. 2017;19(4):21. https://doi.org/10.1007/s11926-017-0642-z .
doi: 10.1007/s11926-017-0642-z
pubmed: 28365920
pmcid: 5502109
Dures E, Hewlett S, Lord J, Bowen C, McHugh N, PROMPT Study Group, et al. Important treatment outcomes for patients with psoriatic arthritis: a multisite qualitative study. Patient. 2017;10(4):455–62. https://doi.org/10.1007/s40271-017-0221-4 .
doi: 10.1007/s40271-017-0221-4
pubmed: 28229377
pmcid: 5534194
Tillett W, Merola JF, Thaci D, Holdsworth E, Booth N, Lobosco LS, et al. Disease characteristics and the burden of joint and skin involvement amongst people with psoriatic arthritis: a population survey. Rheumatol Ther. 2020;7(3):617–37. https://doi.org/10.1007/s40744-020-00221-8 .
doi: 10.1007/s40744-020-00221-8
pubmed: 32700230
pmcid: 7410983
Coates LC, Kavanaugh A, Mease PJ, Soriano ER, Laura Acosta-Felquer M, Armstrong AW, et al. Group for research and assessment of psoriasis and psoriatic arthritis 2015 treatment recommendations for psoriatic arthritis. Arthritis Rheumatol. 2016;68(5):1060–71. https://doi.org/10.1002/art.39573 .
doi: 10.1002/art.39573
pubmed: 26749174
Gossec L, Smolen JS, Ramiro S, de Wit M, Cutolo M, Dougados M, et al. European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update. Ann Rheum Dis. 2016;75(3):499–510. https://doi.org/10.1136/annrheumdis-2015-208337 .
doi: 10.1136/annrheumdis-2015-208337
pubmed: 26644232
Singh JA, Guyatt G, Ogdie A, Gladman DD, Deal C, Deodhar A, et al. Special article: 2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis. Arthritis Rheumatol. 2019;71(1):5–32. https://doi.org/10.1002/art.40726 .
doi: 10.1002/art.40726
pubmed: 30499246
Kjeken I, Dagfinrud H, Mowinckel P, Uhlig T, Kvien TK, Finset A. Rheumatology care: involvement in medical decisions, received information, satisfaction with care, and unmet health care needs in patients with rheumatoid arthritis and ankylosing spondylitis. Arthritis Rheum. 2006;55(3):394–401. https://doi.org/10.1002/art.21985 .
doi: 10.1002/art.21985
pubmed: 16739186
Leung YY, Tam LS, Lee KW, Leung MH, Kun EW, Li EK. Involvement, satisfaction and unmet health care needs in patients with psoriatic arthritis. Rheumatology (Oxford). 2009;48(1):53–6. https://doi.org/10.1093/rheumatology/ken410 .
doi: 10.1093/rheumatology/ken410
Aletaha D, Husni ME, Merola JF, Ranza R, Bertheussen H, Lippe R, et al. Treatment mode preferences in psoriatic arthritis: a qualitative multi-country study. Patient Prefer Adherence. 2020;14:949–61. https://doi.org/10.2147/PPA.S242336 .
doi: 10.2147/PPA.S242336
pubmed: 32606613
pmcid: 7293411
Coates LC, Helliwell PS. Methotrexate efficacy in the tight control in psoriatic arthritis study. J Rheumatol. 2016;43(2):356–61. https://doi.org/10.3899/jrheum.150614 .
doi: 10.3899/jrheum.150614
pubmed: 26669913
Coates LC, Merola JF, Grieb SM, Mease PJ, Callis DK. Methotrexate in psoriasis and psoriatic arthritis. J Rheumatol Suppl. 2020;96:31–5. https://doi.org/10.3899/jrheum.200124 .
doi: 10.3899/jrheum.200124
pubmed: 32482765
Kingsley GH, Kowalczyk A, Taylor H, Ibrahim F, Packham JC, McHugh NJ, et al. A randomized placebo-controlled trial of methotrexate in psoriatic arthritis. Rheumatology (Oxford). 2012;51(8):1368–77. https://doi.org/10.1093/rheumatology/kes001 .
doi: 10.1093/rheumatology/kes001
Orbai AM, de Wit M, Mease P, Shea JA, Gossec L, Leung YY, et al. International patient and physician consensus on a psoriatic arthritis core outcome set for clinical trials. Ann Rheum Dis. 2017;76(4):673–80. https://doi.org/10.1136/annrheumdis-2016-210242 .
doi: 10.1136/annrheumdis-2016-210242
pubmed: 27613807
Cheung KL, Wijnen BF, Hollin IL, Janssen EM, Bridges JF, Evers SM, et al. Using best–worst scaling to investigate preferences in health care. Pharmacoeconomics. 2016;34(12):1195–209. https://doi.org/10.1007/s40273-016-0429-5 .
doi: 10.1007/s40273-016-0429-5
pubmed: 27402349
pmcid: 5110583
Parvin S, Wang P, Uddin J, Wright LT. Using best–worst scaling method to examine consumers’ value preferences: a multidimensional perspective. Cogent Bus Manag. 2016;3(1):1199110. https://doi.org/10.1080/23311975.2016.1199110 .
doi: 10.1080/23311975.2016.1199110
Flynn TN, Louviere JJ, Peters TJ, Coast J. Best–worst scaling: what it can do for health care research and how to do it. J Health Econ. 2007;26(1):171–89. https://doi.org/10.1016/j.jhealeco.2006.04.002 .
doi: 10.1016/j.jhealeco.2006.04.002
pubmed: 16707175
Yuan Z, Levitan B, Burton P, Poulos C, Hauber AB, Berlin J. Relative importance of benefits and risks associated with antithrombotic therapies of acute coronary syndrome: patient and physician perspectives. Value Health. 2013;16(3):A292–3. https://doi.org/10.1016/j.jval.2013.03.1517 .
doi: 10.1016/j.jval.2013.03.1517
Hauber AB, Mohamed AF, Johnson FR, Cook M, Arrighi HM, Zhang J, et al. Understanding the relative importance of preserving functional abilities in Alzheimer’s disease in the United States and Germany. Curr Med Res Opin. 2014;30(9):1733–41. https://doi.org/10.1007/s11136-013-0620-5 .
doi: 10.1007/s11136-013-0620-5
Peay HL, Hollin I, Fischer R, Bridges JF. A community-engaged approach to quantifying caregiver preferences for the benefits and risks of emerging therapies for Duchenne muscular dystrophy. Clin Ther. 2014;36(5):624–37. https://doi.org/10.1016/j.clinthera.2014.04.011 .
doi: 10.1016/j.clinthera.2014.04.011
pubmed: 24852596
Ross M, Bridges JF, Ng X, Wagner LD, Frosch E, Reeves G, et al. A best–worst scaling experiment to prioritize caregiver concerns about ADHD medication for children. Psychiatr Serv. 2015;66(2):208–11. https://doi.org/10.1176/appi.ps.201300525 .
doi: 10.1176/appi.ps.201300525
pubmed: 25642618
Ungar WJ, Hadioonzadeh A, Najafzadeh M, Tsao NW, Dell S, Lynd LD. Quantifying preferences for asthma control in parents and adolescents using best–worst scaling. Respir Med. 2014;108(6):842–51. https://doi.org/10.1016/j.rmed.2014.03.014 .
doi: 10.1016/j.rmed.2014.03.014
pubmed: 24780719
Khare M, Federer WT. A simple construction procedure for resolvable incomplete block designs for any number of treatments. Biom J. 1981;23(2):121–32. https://doi.org/10.1002/bimj.4710230203 .
doi: 10.1002/bimj.4710230203
Train K. Discrete choice methods with simulation. 2nd ed. Cambridge: Cambridge University Press; 2009.
Train K, Sonnier G. Mixed logit with bounded distributions of correlated partworths. In: Applications of simulation methods in environmental and resource economics. Dordrecht: Springer; 2005.
Ogdie A, Michaud K, Nowak M, Bruce R, Cantor S, Hintzen C, et al. Patient’s experience of psoriatic arthritis: a conceptual model based on qualitative interviews. Arthritis Care Res. 2020;6(3): e001321. https://doi.org/10.1136/rmdopen-2020-001321 .
doi: 10.1136/rmdopen-2020-001321
Sunkureddi P, Doogan S, Heid J, Benosman S, Ogdie A, Martin L, et al. Evaluation of self-reported patient experiences: insights from digital patient communities in psoriatic arthritis. J Rheumatol. 2018;45(5):638–47. https://doi.org/10.3899/jrheum.170500 .
doi: 10.3899/jrheum.170500
pubmed: 29449495
Husni ME, Fernandez A, Hauber B, Singh R, Posner J, Sutphin J, et al. Comparison of US patient, rheumatologist, and dermatologist perceptions of psoriatic disease symptoms: results from the DISCONNECT study. Arthritis Res Ther. 2018;20(1):102. https://doi.org/10.1186/s13075-018-1601-4 .
doi: 10.1186/s13075-018-1601-4
pubmed: 29848385
pmcid: 5977464
Tillett W, Dures E, Hewlett S, Helliwell PS, FitzGerald O, Brooke M, et al. A multicenter nominal group study to rank outcomes important to patients, and their representation in existing composite outcome measures for psoriatic arthritis. J Rheumatol. 2017;44(10):1445–52. https://doi.org/10.3899/jrheum.161459 .
doi: 10.3899/jrheum.161459
pubmed: 28765241
Sandikci SC, Colak S, Aydogan Baykara R, Oktem A, Cure E, Omma A, et al. Evaluation of restless legs syndrome and sleep disorders in patients with psoriatic arthritis. Z Rheumatol. 2019;78(10):987–95. https://doi.org/10.1007/s00393-018-0562-y .
doi: 10.1007/s00393-018-0562-y
pubmed: 30421034
Skougaard M, Jorgensen TS, Rifbjerg-Madsen S, Coates LC, Egeberg A, Amris K, et al. Relationship between fatigue and inflammation, disease duration, and chronic pain in psoriatic arthritis: an observational DANBIO registry study. J Rheumatol. 2020;47(4):548–52. https://doi.org/10.3899/jrheum.181412 .
doi: 10.3899/jrheum.181412
pubmed: 31308213
Eder L, Thavaneswaran A, Chandran V, Cook R, Gladman DD. Factors explaining the discrepancy between physician and patient global assessment of joint and skin disease activity in psoriatic arthritis patients. Arthritis Care Res (Hoboken). 2015;67(2):264–72. https://doi.org/10.1002/acr.22401 .
doi: 10.1002/acr.22401
Katchamart W, Trudeau J, Phumethum V, Bombardier C. Efficacy and toxicity of methotrexate (MTX) monotherapy versus MTX combination therapy with non-biological disease-modifying antirheumatic drugs in rheumatoid arthritis: a systematic review and meta-analysis. Ann Rheum Dis. 2009;68(7):1105–12. https://doi.org/10.1136/ard.2008.099861 .
doi: 10.1136/ard.2008.099861
pubmed: 19054823
Van den Bosch F, Coates L. Clinical management of psoriatic arthritis. Lancet. 2018;391(10136):2285–94. https://doi.org/10.1016/s0140-6736(18)30949-8 .
doi: 10.1016/s0140-6736(18)30949-8
pubmed: 29893227
Shay LA, Lafata JE. Where is the evidence? A systematic review of shared decision making and patient outcomes. Med Decis Making. 2015;35(1):114–31. https://doi.org/10.1177/0272989X14551638 .
doi: 10.1177/0272989X14551638
pubmed: 25351843
Ogdie A, Coates LC, Mease P. Measuring outcomes in psoriatic arthritis. Arthritis Care Res (Hoboken). 2020;72(Suppl 10):82–109. https://doi.org/10.1002/acr.24242 .
doi: 10.1002/acr.24242
Xu Y, Sudharshan L, Hsu M-A, Koenig AS, Cappelleri JC, Liu WF, et al. Patient preferences associated with therapies for psoriatic arthritis: a conjoint analysis. Am Health Drug Benefits. 2018;11(8):408–16.
pubmed: 30647828
pmcid: 6306099